Placental imbalance of vasoactive factors does not affect pregnancy outcome in patients treated with Cyclosporine A after transplantation

American Journal of Kidney Diseases

Volumn 39, Issue 4, 2002, Pages 776-783

  Di Paolo, Salvatore ^a   Monno, Raffaella ^a   Stallone, Giovanni ^a   Grandaliano, Giuseppe ^a   Schena, Antonio ^a   Greco, Pantaleo ^a   Volpe, Paolo ^a   Resta, Leonardo ^a   Selvaggi, Luigi ^a   Schena, F Paolo ^a   Gesualdo, Loreto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cyclosporine A (CsA); Endothelin 1 (ET 1); Human placenta; In situ hybridization; Nitric oxide synthase (NOS); Tissue factor (TF)

Indexed keywords

CYCLOSPORIN A; ENDOTHELIN 1; MESSENGER RNA; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; THROMBOPLASTIN; VASOACTIVE AGENT;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; FETUS GROWTH; FETUS OUTCOME; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PLACENTA; PLACENTA CIRCULATION; PLACENTA WEIGHT; PREGNANCY;

EID: 0036201177     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.31998     Document Type: Article

References (41)

1. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy
2. Heparin suppresses cyclosporine-induced endothelin-1 synthesis in rat endothelial cells
3. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms
4. Imbalance in endothelial vasoactive factors as a possible cause of cyclosporin toxicity: A role for endothelin-converting enzyme
5. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine
6. Medical management of the pregnant transplant recipient
7. Immunologic evaluation of infants from cyclosporine treated kidney transplanted mothers during the first year of life. Analysis of lymphocyte subpopulations and immunoglobulin serum levels
8. Pregnancy outcome after cyclosporine therapy during therapy: A metaanalysis
9. Angiogenesis in the placenta
10. Endothelin-1-induced placental and fetal growth restriction in the rat
11. L-Arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat
12. Disturbed nitric oxide/endothelin-1 equilibrium in cultured human placental endotheliocytes in preeclampsia
13. Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas
14. Endothelin-1 in feto-placental tissues from normotensive pregnant women and women with pre-eclampsia
15. Nitric oxide dysfunction in the pathophysiology of preeclampsia
16. Expression of nitric oxide synthase by syncytiotrophoblast in human placental villi
17. Molecular cloning and characterization of human endothelial nitric oxide synthase
18. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes
19. Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells
20. Tissue factor, plasminogen activator inhibitor 1 and thrombin receptor expression in human crescentic glomerulonephritis
21. In situ hybridization for pro-collagen types I, III and IV mRNA in normal and fibrotic rat liver: Evidence for predominant expression in non parenchymal liver cells
22. Expression of platelet-derived growth factor receptors in normal and diseased human kidney
23. The nitric oxide pathway in pre-eclampsia: Pathophysiological implications
24. Animal models of preeclampsia
25. The role of nitric oxide in the pathogenesis of pre-eclampsia
26. Reduction of placental nitric oxide synthase activity in pre-eclampsia
27. Nitric oxide synthase activity and Doppler parameters in the fetoplacental and uteroplacental circulation in preeclampsia
28. Regulation of nitric oxide synthase activity by tetrahydrobiopterin in human placentae from normal and pre-eclamptic pregnancies
29. Endothelial nitric oxide synthase in placental villous tissue from normal, pre-eclamptic and intrauterine growth restricted pregnancies
30. Placental expression of endothelial constitutive nitric oxide synthase mRNA in pregnancy complicated by preeclampsia
31. Placental nitric oxide synthase (NOS) activity and nitric oxide (NO) production in normal pregnancy, pre-eclampsia and eclampsia
32. Nitrovasodilators - Will they be useful in lowering uterine artery resistance in pre-eclampsia and intrauterine growth restriction?
33. Tissue factor: Identification and characterization of cell types in human placentae
34. Regulation of the tissue factor gene
35. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia
36. Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite
37. Mechanisms of action of new immunosuppressive drugs
38. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis
39. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: A role for tissue factor gene expression
40. Inhibition of transcription factors by anti-inflammatory and anti-rheumatic drugs: Can variability in response be overcome?
41. Cyclosporine A inhibits tissue factor expression in monocytes/macrophages